Evidence for an Unanticipated Relationship between Undifferentiated Pleomorphic Sarcoma and Embryonal Rhabdomyosarcoma

Cancer Cell

Volumn 19, Issue 2, 2011, Pages 177-191

  Rubin, Brian P ^a   Nishijo, Koichi ^b   Chen, Hung I Harry ^b   Yi, Xiaolan ^b   Schuetze, David P ^a   Pal, Ranadip ^c   Prajapati, Suresh I ^b   Abraham, Jinu ^b   Arenkiel, Benjamin R ^d   Chen, Qing Rong ^e   Davis, Sean ^e   McCleish, Amanda T ^b   Capecchi, Mario R ^f   Michalek, Joel E ^b   Zarzabal, Lee Ann ^b   Khan, Javed ^e   Yu, Zhongxin ^g   Parham, David M ^g   Barr, Frederic G ^h   Meltzer, Paul S ^e   Chen, Yidong ^b   Keller, Charles ^b,i,j   more..

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Department of Electrical and Computer Engineering   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g University of Oklahoma Medical Center   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ Mays Cancer Center at UT Health San Antonio   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; PROTEIN PATCHED 1; RETINOBLASTOMA PROTEIN; RETINOBLASTOMA PROTEIN 1; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION; EMBRYONAL RHABDOMYOSARCOMA; GENE MUTATION; HUMAN; MYOBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SARCOMA; SKELETAL MUSCLE; UNDIFFERENTIATED PLEOMORPHIC SARCOMA;

EID: 79751484162     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.12.023     Document Type: Article

References (62)

1. Arndt C.A., Hammond S., Rodeberg D., Qualman S. Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: Results from IRS IV. J. Pediatr. Hematol. Oncol. 2006, 28:563-567.
2. Barr F.G., Smith L.M., Lynch J.C., Strzelecki D., Parham D.M., Qualman S.J., Breitfeld P.P. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. J. Mol. Diagn. 2006, 8:202-208.
3. Beauchamp J.R., Heslop L., Yu D.S., Tajbakhsh S., Kelly R.G., Wernig A., Buckingham M.E., Partridge T.A., Zammit P.S. Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J. Cell. Biol. 2000, 151:1221-1234.
4. Beddis I.R., Mott M.G., Bullimore J. Case report: nasopharyngeal rhabdomyosarcoma and Gorlin's naevoid basal cell carcinoma syndrome. Med. Pediatr. Oncol. 1983, 11:178-179.
5. Breneman J.C., Lyden E., Pappo A.S., Link M.P., Anderson J.R., Parham D.M., Qualman S.J., Wharam M.D., Donaldson S.S., Maurer H.M., et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 2003, 21:78-84.
6. Brown C.B., Engleka K.A., Wenning J., Min Lu M., Epstein J.A. Identification of a hypaxial somite enhancer element regulating Pax3 expression in migrating myoblasts and characterization of hypaxial muscle Cre transgenic mice. Genesis 2005, 41:202-209.
7. Chen Y., Takita J., Hiwatari M., Igarashi T., Hanada R., Kikuchi A., Hongo T., Taki T., Ogasawara M., Shimada A., Hayashi Y. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 2006, 45:583-591.
8. Cornelison D.D., Wold B.J. Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev. Biol. 1997, 191:270-283.
9. Davicioni E., Finckenstein F.G., Shahbazian V., Buckley J.D., Triche T.J., Anderson M.J. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006, 66:6936-6946.
10. Davicioni E., Anderson M.J., Finckenstein F.G., Lynch J.C., Qualman S.J., Shimada H., Schofield D.E., Buckley J.D., Meyer W.H., Sorensen P.H., Triche T.J. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am. J. Pathol. 2009, 174:550-564.
11. De Chiara A., T'Ang A., Triche T.J. Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas. J. Natl. Cancer Inst. 1993, 85:152-157.
12. Diller L., Sexsmith E., Gottlieb A., Li F.P., Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J. Clin. Invest. 1995, 95:1606-1611.
13. Doyle B., Morton J.P., Delaney D.W., Ridgway R.A., Wilkins J.A., Sansom O.J. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J. Pathol. 2010, 222:129-137.
14. Fletcher C.D.M., Unni K.K., Mertens F. Pleomorphic malignant fibrous histiocytoma/undifferentiated high grade pleomorphic sarcoma. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone 2002, IARC Press, Lyon, France.
15. Fukada S., Uezumi A., Ikemoto M., Masuda S., Segawa M., Tanimura N., Yamamoto H., Miyagoe-Suzuki Y., Takeda S. Molecular signature of quiescent satellite cells in adult skeletal muscle. Stem Cells 2007, 25:2448-2459.
16. Gattenloehner S., Dockhorn-Dworniczak B., Leuschner I., Vincent A., Muller-Hermelink H.K., Marx A. A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas. J. Mol. Diagn. 1999, 1:23-31.
17. Gerber A.N., Wilson C.W., Li Y.J., Chuang P.T. The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting MyoD-mediated transcriptional activation. Oncogene 2007, 26:1122-1136.
18. Gorlin R.J. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987, 66:98-113.
19. Grass B., Wachtel M., Behnke S., Leuschner I., Niggli F.K., Schäfer B.W. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology 2009, 54:873-879.
20. Gurney J.G., Young J.L., Roffers S.D., Smith M.A., Bunin G.R. Soft tissue sarcomas. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. National Cancer Institute, SEER Program. NIH Pub. No. 99-4649 1999, National Cancer Institute, Bethesda, MD. L.A.G. Ries, M.A. Smith, J.G. Gurney, M. Linet, T. Tamra, J.L. Young, G.R. Bunin (Eds.).
21. Hahn H., Wojnowski L., Zimmer A.M., Hall J., Miller G., Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat. Med. 1998, 4:619-622.
22. Haldar M., Karan G., Tvrdik P., Capecchi M.R. Two cell lineages, myf5 and myf5- independent, participate in mouse skeletal myogenesis. Dev. Cell 2008, 14:437-445.
23. Hettmer S., Wagers A.J. Muscling in: uncovering the origins of rhabdomyosarcoma. Nat. Med. 2010, 16:171-173.
24. Hosoyama T., Nishijo K., Garcia M.M., Schaffer B.S., Ohshima-Hosoyama S., Prajapati S.I., Davis M.D., Grant W.F., Scheithauer B.W., Marks D.L., et al. A postnatal Pax7+ progenitor gives rise to pituitary adenomas. Genes Cancer 2010, 1:388-402.
25. Huh M.S., Parker M.H., Scime A., Parks R., Rudnicki M.A. Rb is required for progression through myogenic differentiation but not maintenance of terminal differentiation. J. Cell Biol. 2004, 166:865-876.
26. Keller C., Arenkiel B.R., Coffin C.M., El-Bardeesy N., DePinho R.A., Capecchi M.R. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 2004, 18:2614-2626.
27. Kleinerman R.A., Tucker M.A., Abramson D.H., Seddon J.M., Tarone R.E., Fraumeni J.F. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J. Natl. Cancer Inst. 2007, 99:24-31.
28. Kohashi K., Oda Y., Yamamoto H., Tamiya S., Takahira T., Takahashi Y., Tajiri T., Taguchi T., Suita S., Tsuneyoshi M. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J. Cancer Res. Clin. Oncol. 2008, 134:1097-1103.
29. Kuang S., Kuroda K., Le Grand F., Rudnicki M.A. Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell 2007, 129:999-1010.
30. Lae M., Ahn E.H., Mercado G.E., Chuai S., Edgar M., Pawel B.R., Olshen A., Barr F.G., Ladanyi M. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX- FKHR fusion-negative embryonal rhabdomyosarcomas. J. Pathol. 2007, 212:143-151.
31. Lagha M., Brunelli S., Messina G., Cumano A., Kume T., Relaix F., Buckingham M.E. Pax3:Foxc2 reciprocal repression in the somite modulates muscular versus vascular cell fate choice in multipotent progenitors. Dev. Cell 2009, 17:892-899.
32. Langenau D.M., Keefe M.D., Storer N.Y., Guyon J.R., Kutok J.L., Le X., Goessling W., Neuberg D.S., Kunkel L.M., Zon L.I. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 2007, 21:1382-1395.
33. Leuschner I., Newton W.A., Schmidt D., Sachs N., Asmar L., Hamoudi A., Harms D., Maurer H.M. Spindle cell variants of embryonal rhabdomyosarcoma in the paratesticular region. A report of the Intergroup Rhabdomyosarcoma Study. Am. J. Surg. Pathol. 1993, 17:221-230.
34. Li F.P., Fraumeni J.F. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J. Natl. Cancer Inst. 1969, 43:1365-1373.
35. Malkin D., Chilton-MacNeill S., Meister L.A., Sexsmith E., Diller L., Garcea R.L. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene 2001, 20:4441-4449.
36. Martinelli S., McDowell H.P., Vigne S.D., Kokai G., Uccini S., Tartaglia M., Dominici C. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes Cancer 2009, 48:975-982.
37. McLoon L.K., Rowe J., Wirtschafter J., McCormick K.M. Continuous myofiber remodeling in uninjured extraocular myofibers: myonuclear turnover and evidence for apoptosis. Muscle Nerve 2004, 29:707-715.
38. Messina G., Sirabella D., Monteverde S., Galvez B.G., Tonlorenzi R., Schnapp E., De Angelis L., Brunelli S., Relaix F., Buckingham M., Cossu G. Skeletal muscle differentiation of embryonic mesoangioblasts requires pax3 activity. Stem Cells 2009, 27:157-164.
39. Morotti R.A., Nicol K.K., Parham D.M., Teot L.A., Moore J., Hayes J., Meyer W., Qualman S.J. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am. J. Surg. Pathol. 2006, 30:962-968.
40. Nakayama R., Nemoto T., Takahashi H., Ohta T., Kawai A., Seki K., Yoshida T., Toyama Y., Ichikawa H., Hasegawa T. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod. Pathol. 2007, 20:749-759.
41. Nishijo K., Hosoyama T., Bjornson C.R., Schaffer B.S., Prajapati S.I., Bahadur A.N., Hansen M.S., Blandford M.C., McCleish A.T., Rubin B.P., et al. Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J. 2009, 23:2681-2690.
42. Ognjanovic S., Linabery A.M., Charbonneau B., Ross J.A. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 2009, 115:4218-4226.
43. Oue T., Yoneda A., Uehara S., Yamanaka H., Fukuzawa M. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J. Pediatr. Surg. 2010, 45:387-392.
44. Pastore G., Peris-Bonet R., Carli M., Martinez-Garcia C., Sanchez de Toledo J., Steliarova-Foucher E. Childhood soft tissue sarcomas incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 2006, 42:2136-2149.
45. Porter J.D., Merriam A.P., Khanna S., Andrade F.H., Richmonds C.R., Leahy P., Cheng G., Karathanasis P., Zhou X., Kusner L.L., et al. Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice. FASEB J. 2003, 17:893-895.
46. Qualman S., Lynch J., Bridge J., Parham D., Teot L., Meyer W., Pappo A. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer 2008, 113:3242-3247.
47. Qualman S.J., Coffin C.M., Newton W.A., Hojo H., Triche T.J., Parham D.M., Crist W.M. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr. Dev. Pathol. 1998, 1:550-561.
48. Relaix F., Montarras D., Zaffran S., Gayraud-Morel B., Rocancourt D., Tajbakhsh S., Mansouri A., Cumano A., Buckingham M. Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J. Cell Biol. 2006, 172:91-102.
49. Seale P., Bjork B., Yang W., Kajimura S., Chin S., Kuang S., Scime A., Devarakonda S., Conroe H.M., Erdjument-Bromage H., et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature 2008, 454:961-967.
50. Siu F.K., Sham M.H., Chow B.K. Secretin, a known gastrointestinal peptide, is widely expressed during mouse embryonic development. Gene Expr. Patterns 2005, 5:445-451.
51. Smith L.M., Anderson J.R., Coffin C.M. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS). Med. Pediatr. Oncol. 2002, 38:398-404.
52. Stratton M.R., Fisher C., Gusterson B.A., Cooper C.S. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989, 49:6324-6327.
53. Suh C.H., Ordonez N.G., Mackay B. Malignant fibrous histiocytoma: an ultrastructural perspective. Ultrastruct. Pathol. 2000, 24:243-250.
54. Sumino Y., Hirata Y., Sato F., Mimata H. Growth mechanism of satellite cells in human urethral rhabdosphincter. Neurourol. Urodyn. 2007, 26:552-561.
55. Takahashi Y., Oda Y., Kawaguchi K., Tamiya S., Yamamoto H., Suita S., Tsuneyoshi M. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod. Pathol. 2004, 17:660-669.
56. Tiffin N., Williams R.D., Shipley J., Pritchard-Jones K. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br. J. Cancer 2003, 89:327-332.
57. Tostar U., Malm C.J., Meis-Kindblom J.M., Kindblom L.G., Toftgard R., Unden A.B. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J. Pathol. 2006, 208:17-25.
58. Tsumura H., Yoshida T., Saito H., Imanaka-Yoshida K., Suzuki N. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene 2006, 25:7673-7679.
59. Vogel K.S., Klesse L.J., Velasco-Miguel S., Meyers K., Rushing E.J., Parada L.F. Mouse tumor model for neurofibromatosis type 1. Science 1999, 286:2176-2179.
60. Weiss S.W.G., John R. Malignant fibrous histiocytoma. Enzinger and Weiss's Soft Tissue Tumors 2007, Mosby, St Louis. S.W.G. Weiss, R. John (Eds.).
61. Wexler L.H., Ladanyi M. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. J. Clin. Oncol. 2010, 28:2126-2128.
62. Williamson D., Missiaglia E., de Reyniès A., Pierron G., Thuille B., Palenzuela G., Thway K., Orbach D., Laé M., Fréneaux P., et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 2010, 28:2151-2158.